Incyte

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Marketwatch
Eli Lilly
Incyte
olumiant
COVID-19
remdesivir
Gilead Sciences
Flag link:
Karuna and Incyte scrap programs; More cash for the SPACs
Karuna and Incyte scrap programs; More cash for the SPACs
Endpoints
Karuna Therapeutics
Eli Lilly
Incyte
SPAC
Flag link:
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Flag link:
Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Endpoints
ruxolitinib
Novartis
Incyte
graft vs host disease
Flag link:
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
Incyte
earnings
Flag link:
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Novartis
Incyte
AACR
lung cancer
MET inhibitors
capmatinib
Flag link:
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Novartis
Incyte
Jakafi
clinical trials
COVID-19
cytokine storm
graft vs host disease
Flag link:
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Incyte
Pemazyre
pemigatinib
bile duct cancer
cholangiocarcinoma
FDA
Flag link:
Incyte, Novartis launch drug study to treat coronavirus complication
Incyte, Novartis launch drug study to treat coronavirus complication
Marketwatch
Incyte
Novartis
cytokine storm
COVID-19
clinical trials
Jakafi
Flag link:
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
cancer
COVID-19
Incyte
Jakafi
Flag link:
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Eli Lilly
Incyte
breakthrough therapy
FDA
baricitinib
alopecia areata
Flag link:
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Fierce Biotech
Incyte
ruxolitinib
clinical trials
atopic dermatitis
Flag link:
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Fierce Pharma
Incyte
Jakafi
pemigatinib
Flag link:
Incyte Earnings, Revenue Beat in Q4
Incyte Earnings, Revenue Beat in Q4
Yahoo/Investing.com
Incyte
earnings
Flag link:
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Eli Lilly
Incyte
olumiant
eczema
clinical trials
atopic dermatitis
Flag link:
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Flag link:
Incyte's skin disease drug meets main goal in late-stage study
Incyte's skin disease drug meets main goal in late-stage study
Yahoo/Reuters
Incyte
clinical trials
atopic dermatitis
ruxolitinib
Flag link:
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Incyte
MorphoSys
lymphoma
tafasitamab
Flag link:
Incyte stock slammed after study fails to hit goal
Incyte stock slammed after study fails to hit goal
Marketwatch
Incyte
clinical trials
itacitinib
graft vs host disease
Flag link:
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Incyte
Jakafi
innovation
Flag link:

Pages